ASCO GU: radium-233 Alpharadin significantly prolongs time to first Skeletal Related Event
The abstracts for the forthcoming American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium (ASCO GU) have been released and offer insight into some of the new data that will be presented at the meeting.
As expected, there is no change to data presented in Stockholm that showed radium-223 (Alpharadin) improves both Overall Survival and Skeletal Related Events:
radium-223 Overall Survival Benefit
median 14.0 vs 11.2 months; P value = 0.00185; HR = 0.695
radium-223 time to first SRE
median 13.6 vs 8.4 months; P value = 0.00046; HR = 0.610
However, the meeting abstract published today shows that radium-223 in bone-metastatic castration resistant prostate cancer patients (CRPC), not only significantly prolonged time to first skeletal related event (SRE), but significantly prolonged 3 out of the 4 SRE components:
- time to spinal cord compression,
- time to pathological bone fracture
- time to external beam radiation
No significant improvement in the SRE component of time to surgical intervention was seen with radium-223.
Subscribers to Premium Content can login to read commentary by Dr Oliver Sartor on the clinical significance of this data:
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
One Response to “ASCO GU: radium-233 Alpharadin significantly prolongs time to first Skeletal Related Event”
[…] For those of you interested in Alpharadin (radium-225) in castrate-resistant prostate cancer (CRPC), check out the update of Dr Oliver Sartor’s presentation, which is covered on Biotech Strategy Blog. […]
Comments are closed.